NASDAQ: PHHPark Ha Biological Technology Co Ltd Stock
$13.71+0.21 (+1.56%)
Updated Apr 22, 2025
PHH Price
$13.71
Fair Value Price
N/A
Market Cap
$359.20M
52 Week Low
$3.70
52 Week High
$16.56
P/E
685.5x
P/B
238.5x
P/S
N/A
PEG
22.7x
Dividend Yield
N/A
Revenue
$2.38M
Earnings
$478.56k
Gross Margin
91.8%
Operating Margin
33.31%
Profit Margin
20.1%
Debt to Equity
1.05
Operating Cash Flow
$960k
Beta
-0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Household & Personal Product
Industry Rating
C
PHH
Ranked#11 of 25
Ranked#11 of 25
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.35 | B | |
| $4.08 | C | |
| $65.43 | C |
Be the first to know about important PHH news, forecast changes, insider trades & much more!
PHH News
Overview
Due Diligence Score
–
Industry Average (33)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHH ($13.71) is trading above its intrinsic value of $0.31, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHH is poor value based on its earnings relative to its share price (685.5x), compared to the US market average (28.14x)
P/E vs Market Valuation
PHH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PHH due diligence checks available for Premium users.
Valuation
PHH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
685.5x
Industry
26.2x
Market
28.14x
PHH is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PHH is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PHH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
238.5x
Industry
7.56x
PHH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHH price to earnings growth (PEG)
For valuing profitable companies with growth potential
PHH is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
PHH's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PHH's Earnings (EBIT) of $793.42k... subscribe to Premium to read more.
Interest Coverage Financials
PHH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.1M
Liabilities
$1.6M
Debt to equity
1.05
PHH's short-term assets ($2.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHH's short-term assets ($2.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PHH's operating cash flow ($960.47k)... subscribe to Premium to read more.
Debt Coverage Financials
PHH vs Household & Personal Product Stocks
Park Ha Biological Technology Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.